The landscape of retesting in childhood-onset idiopathic growth hormone deficiency and its reversibility: a systematic review and meta-analysis.

What It Covers

This meta-analysis looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Children diagnosed with idiopathic isolated growth hormone deficiency (IGHD) are frequently observed to no longer be GH-deficient at a later stage of growth as a result of 'GHD reversal'.

Reevaluation of GH status by stimulation test is currently incorporated into management guidelines at attainment of final height (FH).

Over the past three decades, numerous studies have evaluated reversal rates using different methodologies including crucial parameters like GHD aetiology, GH cut-off and retesting time point, with heterogeneous results.

Who the Included Studies Covered

By PubMed's age tags, the people studied were children.

PubMed, Cochrane Library, TRIP database and NHS Evidence were searched for publications investigating the reversibility of IGHD from database initiation to 30 June 2020 following PRISMA recommendations.

How the Review Was Done

Study cohorts were pooled according to retesting GH cut-off and time point.

Reversal rates were calculated using random-effects models.

What Was Measured

PubMed files the paper under topics including Body Height, Dwarfism, Pituitary, Growth Hormone and Human Growth Hormone.

What This Means in Plain Language

This is a meta-analysis of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (European journal of endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.